Related Experiment Video

Updated: Jul 31, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease

P Nguyen-Ho1, N M Lakkis

  • 1Cardiology Section, Baylor College of Medicine, 6550 Fannin, SM 677, Houston, TX 77030, USA.

Current Atherosclerosis Reports
|March 20, 2001
PubMed

Insights

Platelets play a key role in coronary artery disease and acute coronary syndromes. Glycoprotein IIb/IIIa inhibitors offer a promising therapeutic strategy by blocking platelet aggregation and arterial thrombus formation.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Platelets are increasingly recognized for their critical role in the pathogenesis of coronary artery disease (CAD).
  • Understanding platelet function is crucial for managing atherosclerotic lesions and acute coronary syndromes (ACS).

Purpose of the Study:

  • To summarize platelet function and pathophysiology in the context of cardiovascular disease.
  • To review current glycoprotein IIb/IIIa inhibitors.
  • To discuss pivotal clinical trials involving glycoprotein IIb/IIIa inhibitors.

Main Methods:

  • Literature review of platelet function in CAD.
  • Summary of available glycoprotein IIb/IIIa receptor antagonists.
  • Analysis of key clinical trial outcomes for these agents.

Main Results:

  • Platelet aggregation via the glycoprotein IIb/IIIa receptor is a central mechanism in arterial thrombosis.
  • Glycoprotein IIb/IIIa inhibitors represent a significant advancement in antiplatelet therapy for CAD.
  • Clinical trials demonstrate the efficacy of these inhibitors in reducing thrombotic events.

Conclusions:

  • Targeting the glycoprotein IIb/IIIa receptor is a validated therapeutic approach for managing CAD.
  • Glycoprotein IIb/IIIa inhibitors have a crucial role in the treatment of patients with acute coronary syndromes.
  • Continued research and clinical application of these agents are essential for improving cardiovascular outcomes.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...